> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Fast Track for Conatus Pharma Cirrhosis Drug
- URL: https://www.fdaweb.com/fast-track-for-conatus-pharma-cirrhosis-drug/
- Published: 2016-02-03T12:00:00.000Z
- Updated: 2026-09-15T02:32:55.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5134674

> FDA has granted Conatus Pharmaceuticals a fast track designation for emricasan and its development program for treating liver cirrhosis caused by nonalcoholic steatohepatitis (NASH). “The data from our recently completed Portal Hypertension trial, showing clinically meaningful reductions in hepatic venous pressure gradient (HVPG) in patients with severe portal hypertension after only one month of treatment with emricasan, were a key component of our fast track submission,” the company says.  
>  
> To date, it says, emricasan has been studied in over 650 subjects in 16 clinical trials across a broad range of liver disease etiologies and stages of progression. In multiple clinical trials, emricasan has “demonstrated statistically significant, rapid and sustained reductions in elevated levels of key biomarkers of inflammation and apoptosis that are implicated in the progression of liver disease,” Conatus says. In November, the company announced plans to conduct clinical trials designed to evaluate multiple doses of emricasan over various treatment durations in chronic liver disease of different etiologies and disease stages. “The ENCORE trials are designed to provide further information on doses leading to clinically relevant efficacy, including improvement in biopsy-proven fibrosis and inflammation in patients with NASH fibrosis, and improvement in severe portal hypertension and hepatic function in patients with NASH cirrhosis,” it adds.